Stay updated on Pimavanserin Safety in Neurodegenerative Disease Clinical Trial
Sign up to get notified when there's something new on the Pimavanserin Safety in Neurodegenerative Disease Clinical Trial page.

Latest updates to the Pimavanserin Safety in Neurodegenerative Disease Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference6%
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check44 days agoChange DetectedThe web page has updated its version from v2.14.4 to v2.15.0, indicating a significant revision. The phrase 'Here’s how you know' has been changed to 'Here’s how you know', which does not alter the meaning.SummaryDifference1.0%
- Check51 days agoChange DetectedThe page has updated its version from v2.14.3 to v2.14.4 and removed a date of March 25, 2025, while adding a new date of December 31, 2024.SummaryDifference1%
- Check95 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check109 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
Stay in the know with updates to Pimavanserin Safety in Neurodegenerative Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pimavanserin Safety in Neurodegenerative Disease Clinical Trial page.